FT Options’s Nektar Therapeutics NKTR Stock Holding History

FT Options’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,333	Closed	-$4K	–	253
2017 Q1	$4K	Buy	+2,333	New	+$524K	0.01%	254
2016 Q4	–	Sell	-333	Closed	-$10K	–	335
2016 Q3	$10K	Buy	+333	New	+$85.7K	0.01%	301

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

FT Options's NKTR Position: Q2 2017 in Review

FT Options sold out of Nektar Therapeutics (NKTR) in Q2 2017, closing a stake of 340 shares — an estimated $120K sold.

FT Options first reported a position in NKTR in Q1 2017 and held it in 1 quarter. The position peaked at $120K in Q1 2017. 197 funds tracked by Wall St. Rank hold NKTR as of Q2 2017.

FT Options reported no remaining Nektar Therapeutics position as of Q2 2017 after selling out during the quarter.
FT Options sold 340 Nektar Therapeutics shares in Q2 2017, an estimated $120K.
FT Options first reported a position in Nektar Therapeutics in Q1 2017 and held it in 1 quarter.
FT Options's Nektar Therapeutics position peaked at $120K in Q1 2017.
197 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2017.

Based on FT Options's 13F filing for Q2 2017, filed 11 Aug 2017.